on SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma Revises 2026 Fiscal Outlook and Mid-Term Guidance
SCHOTT Pharma has released its financial projections for the fiscal year 2026, with expectations of revenue growth at constant currencies between 2-5% and an EBITDA margin of approximately 27%. These figures are lower than current market expectations, which anticipate 8.2% growth and a 28.8% EBITDA margin.
The company also updated its mid-term outlook for 2027 to 2029, forecasting a revenue compound annual growth rate (CAGR) of 6-8% and an improvement in EBITDA margin towards 30% in the coming years.
Preliminary results for fiscal year 2025 align with market forecasts, with detailed results scheduled for release on December 11, 2025.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SCHOTT Pharma AG & Co. KGaA news